Background
UNAIDS has provided basic information about the HIV/AIDS epidemic by predicting the number of HIV-infected individuals in each country, in addition to the worldwide data [
1,
2]. The AIDS Epidemic software (EPIMODEL) was developed by the WHO in the late 1980 s to estimate the past and current HIV prevalence, and to make short-term projections of AIDS cases and deaths in areas where AIDS case reporting was largely incomplete and unreliable [
3,
4]. UNAIDS reported that there are 33.4 million people living with HIV/AIDS (PLWHA) worldwide, and 4.7 million HIV-positive individuals were alive in Asia in 2008 [
5]. There is an enormous difference in the national HIV prevalence among Asian countries [
6]. Specifically, south and southeast Asia have a high prevalence, while Korea and Japan have a low prevalence [
7].
A total of 6888 cumulative HIV infections were identified in Korea as of 2009; 82% (5671) of these individuals had been previously living with HIV/AIDS. The number of newly diagnosed individuals is increasing annually [
8]. It is unclear whether the increase is secondary to increased transmission rates or to increased testing and identification. We hoped to estimate the annual number of HIV tests nationwide and compare this to the annual HIV prevalence. However, the nationwide seroprevalence and total number of HIV tests has not been estimated because the number of HIV tests in the hospitals was lacking.
The number of HIV tests in public health centers (PHCs) decreased due to changes in strategies for HIV testing from 1998 in Korea [
9]. In contrast, the number of HIV tests in hospitals has increased since 2000 due to increased medical examinations, including regular health check-ups, tests for pregnant women, and pre-surgical testing. The current proportion of new HIV diagnoses in hospitals is 70% [
10]. PHCs and blood centers manage data of HIV testing through a computerized system and regularly report the number of HIV tests to the Korea Centers for Disease Control and Prevention (KCDC) [
11‐
13]. However, there are no similar reporting systems to identify how many HIV tests are performed in the greater than 5000 Korean hospitals [
14]. Hospital-derived testing data is very important in the estimation of nationwide HIV seroprevalence, and prevalence models or estimation methods are required to estimate the number of HIV tests performed in the hospital.
The nationwide HIV seroprevalence is important for AIDS prevention and evaluation of HIV testing strategies. We therefore estimated the number of HIV tests and HIV seroprevalence in hospitals. We developed a method to estimate the number of HIV tests performed in hospitals, calculated HIV seroprevalence in the hospital setting, and analyzed the trends in HIV seroprevalence.
Results
The proportion of computerized insurance claims was currently more than 95% (Table
1). General hospital and clinic centers have increased for computerization of insurance claims from 53.4% and 25.9% in 2002 to 98.1% and 98.4% in 2008, respectively. The repeated values were the highest in private clinics (P < 0.0001); however, the annual repeated value of private clinics was not increasing (P = 0.4077).
The estimated number of HIV tests and insurance claim proportions in hospitals are summarized, as shown in Table
2. The total number of HIV tests in hospitals increased from 2.8 million in 2002 to 5.0 million in 2008, and also the number of insurance claims for HIV tests increased annually in all hospital types (P < 0.0001). The highest insurance claim proportion for HIV tests was from university medical centers, followed by general hospital and clinic centers.
Table 2
Estimation of insurance claim proportion for HIV testing and the number of HIV test based on hospital type in Korea (2002-2008)
University medical center | No. of institutes†
| 42 | 42 | 43 | 42 | 43 | 43 | 43 |
| No. of institutes participating in survey (%‡)* | - | - | - | 38 (90.5%) | 40 (93.0%) | - | 41 (95.3%) |
| Insurance claim proportion for HIV test§
| 33.9% | 33.9% | 33.9% | 33.9% | 39.7% | 43.1% | 46.5% |
| No. of insurance claims | 188 006 | 232 114 | 268 914 | 311 852 | 408 904 | 480 238 | 560 928 |
| Estimated number of HIV tests | 618 962 | 709 536 | 800 461 | 919 917 | 1 029 985 | 1 114 241 | 1 206 297 |
General hospital | No. of institutes | 241 | 241 | 163 | 215 | 242 | 249 | 268 |
| No. of institutes participating in survey (%‡) | - | - | - | 143 (66.5%) | 164 (67.8%) | - | 141 (52.6%) |
| Insurance claim proportion for HIV test | 21.1% | 21.1% | 21.1% | 21.1% | 24.9% | 31.7% | 38.5% |
| No. of insurance claims | 96 636 | 154 322 | 202 994 | 292 957 | 380 878 | 492 621 | 572 374 |
| Estimated number of HIV tests | 857 660 | 996 436 | 1 142 585 | 1 465 580 | 1 554 503 | 1 590 593 | 1 515 480 |
Clinic center | No. of institutes | 783 | 871 | 314 | 470 | 573 | 759 | 888 |
| No. of institutes participating in survey (%‡) | - | - | - | 63 (13.4%) | 77 (13.4%) | - | 78 (8.9%) |
| Insurance claim proportion for HIV test | 16.8% | 16.8% | 16.8% | 16.8% | 15.9% | 19.2% | 22.4% |
| No. of insurance claims | 40 261 | 80 111 | 107848 | 134 546 | 189 783 | 250 976 | 330 385 |
| Estimated number of HIV tests | 925 285 | 904 841 | 897 835 | 877 184 | 1 234 337 | 1 358 801 | 1 498 916 |
Private clinic | No. of institutes | 22 760 | 23 559 | 1913 | 2028 | 2267 | 2396 | 2448 |
| No. of institutes participating in survey (%)** | - | - | - | 22 (1.1%) | 24 (1.1%) | - | 23 (0.9%) |
| Insurance claim proportion for HIV test | 11.0% | 11.0% | 11.0% | 11.0% | 11.4% | 12.4% | 13.3% |
| No. of insurance claims | 34 862 | 45 544 | 46 475 | 57 637 | 74 952 | 91 242 | 104 338 |
| Estimated number of HIV tests | 360 555 | 456 490 | 455 771 | 552 714 | 690 624 | 772 112 | 822 323 |
Total | No. of insurance claims | 359 765 | 512 098 | 626 231 | 796 794 | 1 054 517 | 1 315 077 | 1 568 025 |
| Estimated number of HIV test | 2 762 462 | 3 067 303 | 3 296 653 | 3 814 395 | 4 509 448 | 4 835 747 | 5 043 015 |
Table
3 shows the estimated number of HIV-tested individuals and HIV seroprevalence in hospitals. A total of 2,662,715 individuals had HIV testing in hospitals in 2002. The estimated number increased to 4,774,625 individuals tested after ongoing annual increases. Women were tested more frequently (53%) than men (47%), and the aged 20-29 groups were higher in 2002 (21%) than in 2008 (16%, P = 0.0024), and the ≥60-year age group was elevated (P < 0.0001). Small towns showed an increasing proportion of tested individuals, as follows: 26% in 2002; 35% in 2005; and 39% in 2008 (P < 0.0001).
Table 3
Estimation of the number of HIV- tested individuals and HIV seroprevalence in hospital in Korea (2002-2008)
Total | 2662715 | 1.1 (1.0,1.3) | 2942022 | 1.5 (1.3,1.6) | 3152536 | 1.5 (1.3,1.6) | 3655715 | 1.4 (1.3,1.6) | 4288267 | 1.4 (1.2,1.5) | 4559827 | 1.3 (1.2,1.4) | 4774625 | 1.3 (1.2,1.4) |
Gender | | | | | | | | | | | | | | |
Men | 1241385(47) | 2.2 (1.9,2.5) | 1366003 (46) | 3.0 (2.7,3.3) | 1475469(47) | 2.9 (2.6,3.1) | 1725043(47) | 2.9 (2.6,3.1) | 2029604(47) | 2.6 (2.4,2.8) | 2157016(47) | 2.5 (2.3,2.7) | 2283012(48) | 2.5 (2.3,2.7) |
Women | 1421330(53) | 0.2 (0.1,0.3) | 1576019(54) | 0.2 (0.1,0.3) | 1677067(53) | 0.2 (0.2,0.3) | 1930672(53) | 0.1 (0.1,0.2) | 2258663(53) | 0.2 (0.2,0.3) | 2402811(53) | 0.2 (0.1,0.2) | 2491613(52) | 0.2 (0.1,0.2) |
Age(years) | | | | | | | | | | | | | | |
<20 | 230182(14) | 0.2 (0.0,0.3) | 265790(14) | 0.2 (0.0,0.4) | 286719(14) | 0.2 (0.0,0.3) | 327129(14) | 0.2 (0.1,0.4) | 368356(14) | 0.2 (0.1,0.4) | 575860(13) | 0.2 (0.1,0.3) | 391628(13) | 0.3 (0.1,0.4) |
20-29 | 415085(21) | 1.4 (1.0,1.7) | 427927(20) | 1.8 (1.4,2.2) | 428347(18) | 2.1 (1.7,2.6) | 483521(17) | 1.6 (1.2,2.0) | 564369(17) | 1.6 (1.3,2.0) | 359699(17) | 2.1 (1.7,2.6) | 583999(16) | 1.5 (1.2,1.8) |
30-39 | 551075(20) | 1.7 (1.3,2.0) | 579531(19) | 2.7 (2.3,3.1) | 594234(18) | 2.8 (2.4,3.2) | 656387(18) | 2.8 (2.4,3.2) | 753751(17) | 2.3 (2.0,2.7) | 770464(17) | 2.1 (1.8,2.5) | 795353(16) | 2.0 (1.7.,2.3) |
40-49 | 527384(17) | 1.6 (1.3,1.9) | 579015(17) | 2.0 (1.6,2.4) | 609748(17) | 1.9 (1.5,2.2) | 698571(18) | 1.8 (1.5,2.2) | 816613(19) | 1.8 (1.5,2.0) | 754847(19) | 2.0 (1.7,2.4) | 867318(19) | 2.2 (1.9,2.5) |
50-59 | 379374(14) | 1.2 (0.8,1.5) | 429129(15) | 1.3 (1.0,1.7) | 465895(15) | 1.2 (0.9,1.5) | 560005(15) | 1.6 (1.3,1.9) | 682309(15) | 1.4 (1.1,1.7) | 855980(15) | 1.1 (0.9,1.3) | 802645(15) | 1.5 (1.3,1.8) |
60≤ | 559617(14) | 0.3 (0.,0.5) | 660629(15) | 0.3 (0.2,0.5) | 767593(17) | 0.4 (0.3,0.5) | 930102(18) | 0.4 (0.3,0.5) | 1102869(18) | 0.6 (0.5,0.7) | 1242976(20) | 0.6 (0.5,0.7) | 1333682(21) | 0.4 (0.3,0.5) |
Region | | | | | | | | | | | | | | |
Metropolitan | 1 961671(74) | 1.2 (1.0,1.3) | 2 114283(72) | 1.5 (1.3,1.6) | 2155559(68) | 1.6 (1.4,1.8) | 2 368915(65) | 1.4 (1.2,1.5) | 2674029(62) | 1.6 (1.4,1.7) | 2799223(61) | 1.6 (1.4,1.7) | 2 917391(61) | 1.6 (1.4,1.7) |
Small town | 701044(26) | 1.0 (0.8,1.3) | 827739(28) | 1.4 (1.2,1.7) | 996977(32) | 1.2 (1.0,1.4) | 1286800(35) | 1.5 (1.3,1.7) | 1614238(38) | 1.0 (0.8,1.1) | 1760604(39) | 0.7 (0.6,0.8) | 1 857234(39) | 0.9 (0.8,1.1) |
The annual HIV seroprevalence was between 1.5 and 1.3 per 10,000 individuals between 2003 and 2008; however, HIV seroprevalence was lower in 2002 than other years. Men had a higher seroprevalence than women and decreased from 3.0 per 10,000 individuals to 2.5 per 10,000 individuals (P = 0.0037); however, the seroprevalence in women (around 0.2 per 10,000 individuals) was stable between 2002 and 2008. The 30-39-year age group had the highest annual HIV seroprevalence, except in 2008, while the seroprevalence in the ≥60-year age group was increased, but there was no statistically significant difference (P = 0.0948). The annual HIV seroprevalence was higher in metropolitan areas than small towns, except in 2005.
Discussion
The nationwide hospital HIV seroprevalence was calculated using a new estimation method in the present study. In 2008, the estimated number of HIV tests and tested individuals in hospitals increased and reached 5.0 million and 4.8 million cases, respectively. The annual HIV seroprevalence in hospitals was between 1.5 and 1.3 per 10,000 individuals during the study period, except 2002. The annual number of HIV-tested individuals in PHCs was approximately 0.3 million and the number in blood centers was approximately 1.6 million in 2008 [
12]. These data led to an estimated 6.6 million as the total number of HIV-tested individuals, including the test-takers at hospitals in the same year. Thus, it is estimated that 13% of the Korean population (49 million) are tested annually [
19]. Of HIV infections, 70% were diagnosed in hospitals, which performed 73% of HIV tests in Korea in 2008. The seroprevalence of HIV in hospitals was higher than the seroprevalence of HIV in blood centers and lower than PHCs when compared with previous results [
13]. Most HIV infections diagnosed in hospitals were tested due to AIDS-related symptoms, pre-surgical evaluations and regular health check-ups [
10]. The number of HIV-tested individuals increased from 0.35 million in 2002 to 1.5 million in 2008; the increased number was supported by annual data of tested individuals who sent insurance claims for HIV tests to HIRA. This result confirmed the increase in number of tested individuals per hospital and institution performing the tests. The main reason for increasing HIV-tested individuals may be the effect of advertisements for AIDS prevention through the mass media (initiated in 2004) and the official announcement of December as AIDS Test Days [
20].
The highest insurance claim proportion for HIV tests in university medical centers is caused by the number of cases including operation, transplantation and severe diseases care which requires HIV test with insurance (Figure
1).
The seroprevalence in women was lower than men, while more women were tested than men. Women between 25 and 34 years of age were tested more frequently than any other age group. This was likely due to required HIV tests during pregnancy. Additionally, the proportion of women ≥ 60 years of age is higher than men, likely due to prolonged life spans in women [
21].
We attempted to use statistical methods that would reduce errors since a perfect estimation without errors was not likely [
4,
22‐
24]. WHO/UNAIDS differentially applied the results from serologic surveys of specific groups, back-calculation methods, ratio methods, and multiplication of estimated annual AIDS cases by 20 according to factors, including year and population characteristics [
4]. These estimation methods might be affected by data quality, representation rate, and modeling assumptions to result in errors. Therefore, estimation methods were improved by development of new methods (workbook method and special computer method) and tool standards to achieve superior estimations [
22‐
24].
UNAIDS currently estimates the HIV prevalence of each country by reflecting population and characteristics through national surveillance and specific surveillance in high-risk groups [
1,
25,
26]. This estimated that 13,000 HIV-infected individuals (95% CI, 7,500-42,000) have survived, and HIV prevalence in individuals 15-49 years of age was estimated at 0.040% (95% CI, 0.00-0.100) in Korea in 2007 [
27]. However, we estimated that the nationwide HIV seroprevalence was 0.014% (95% CI, 0.011-0.016) after adjustment for age and gender in the same year. This seroprevalence was estimated for HIV seroprevalence of PHC visitors (0.043%; 95% CI, 0.027-0.060), blood donors (0.003%; 95% CI, 0.001-0.005) [
13], and hospital visitors (0.015%; 95% CI, 0.012-0.018). The estimated HIV seroprevalence in this study was lower than UNAIDS estimation.
WHO/UNAIDS estimated current Korean HIV/AIDS data based on KCDC reports. This reflected some basic factors, including population, birth rate, death rate, and the number of HIV-infected individuals. However, it did not include advanced factors, such as current prevalence by institutional types or risk groups. The estimated value by the AIDS prediction model (EPP) will be most similar to the true value when it includes as many factors related to HIV prevalence as possible. Therefore, a survey by KCDC should be expanded to more factors affecting WHO/UNAIDS evaluation. UNAIDS estimation used only basic factors, while HIV seroprevalence in this study was estimated using information, such as data from EQAS survey, insurance claim data, and data for HIV tests in blood centers and PHCs. Because of this difference, we think that our results may be closer to the true value than UNAIDS estimation.
In our study, estimation of HIV-tested individuals using insurance data and hospital surveys can include several limitations. First, the number of surveys for clinic centers and private clinics are not as large as other hospital types. However, 12% of clinic centers are not too low by sampling methods for estimation [
28]. Also, the number of tests in private clinics substituted from commercial clinical laboratories was likely accurate because most of the commercial clinical laboratories participated in the survey. Our results can include bias in insurance claim proportions for HIV tests by surveyed hospitals per year [
29]. Second, there are some years in which surveys are missing. Without surveys, insurance claim proportions for HIV tests during 2002-2004 were estimated by that of 2005. Estimation of 2007 was reasonable because it was estimated as the mean of 2006 and 2008, but estimations for 2002 through 2004 appear to be biased and the value near year 2002 has more bias than the true value. There is a need to survey the number of HIV tests in hospitals per year to precisely estimate the insurance claim proportion for HIV tests. Finally, repeated values may be different between individuals with and without insurance claims. We are aware that there could be some bias in the prevalence estimated in the present study. Indeed, previous studies have identified potential biases in assessing the general population HIV prevalence from samples of selected groups such as prenatal clinic users, blood donors and hospital-based studies [
30,
31]. However, the repeated value for individuals with insurance claims was similar to the value of HIV-tested individuals during health check-ups in PHCs [
11]. This report could enforce our assumption for the estimation method.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
MKK and JHL designed and conceived the idea for the study and MKK supervised all aspects of its implementation and coordinated funding for the project. JHL completed the all data analyses and wrote the first draft of the manuscript. KJH contributed to the critical revising for important intellectual content and discussion. JSW contributed to collection EQAS survey data. SSK coordinated funding for the project and contributed to the critical revising for important intellectual content. All authors read and approved the final version of the manuscript as submitted to BMC Public Health.